A novel long-acting phospholipid phase transition gel with progesterone effectively promoted uterine development

IF 4.4 2区医学 Q1 PHARMACOLOGY & PHARMACY

European Journal of Pharmaceutics and Biopharmaceutics Pub Date : 2025-03-05 DOI:10.1016/j.ejpb.2025.114690

Bing Qin , Mengling Yu , Yong Qin , Jianfeng Zuo , Lianwen Qi

{"title":"A novel long-acting phospholipid phase transition gel with progesterone effectively promoted uterine development","authors":"Bing Qin , Mengling Yu , Yong Qin , Jianfeng Zuo , Lianwen Qi","doi":"10.1016/j.ejpb.2025.114690","DOIUrl":null,"url":null,"abstract":"<div><div>Progesterone (PRG), a steroidal hormone, is commonly utilized in the clinical practice of obstetrics and gynecology. The high frequency of PRG injections, however, has brought significant pain and inconvenience to patients. In this study, we developed a long-acting injection leveraging the phase transition mechanism for the long-term treatment in Assisted Reproductive Technology (ART). The components we selected all possess excellent biocompatibility. Pharmacokinetic studies revealed that the PRG-loaded phospholipid phase transition gels (PRG-PPTGs) released the PRG continuously for over 7 days. Notably, pharmacological investigation demonstrated that PRG-PPTGs, when administered weekly, effectively promoted uterine development. Our findings suggested that PRG-PPTGs successfully achieve both the prevention of burst release and the reduction of dosing frequency, highlighting the potential of PPTGs as promising long-acting composite system for hydrophobic drugs.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"210 ","pages":"Article 114690"},"PeriodicalIF":4.4000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0939641125000669","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Progesterone (PRG), a steroidal hormone, is commonly utilized in the clinical practice of obstetrics and gynecology. The high frequency of PRG injections, however, has brought significant pain and inconvenience to patients. In this study, we developed a long-acting injection leveraging the phase transition mechanism for the long-term treatment in Assisted Reproductive Technology (ART). The components we selected all possess excellent biocompatibility. Pharmacokinetic studies revealed that the PRG-loaded phospholipid phase transition gels (PRG-PPTGs) released the PRG continuously for over 7 days. Notably, pharmacological investigation demonstrated that PRG-PPTGs, when administered weekly, effectively promoted uterine development. Our findings suggested that PRG-PPTGs successfully achieve both the prevention of burst release and the reduction of dosing frequency, highlighting the potential of PPTGs as promising long-acting composite system for hydrophobic drugs.

Abstract Image

查看原文本刊更多论文

一种新型长效含黄体酮磷脂相变凝胶能有效促进子宫发育。

黄体酮（PRG）是一种甾体激素，在妇产科的临床实践中被广泛使用。然而，PRG注射的高频率给患者带来了巨大的痛苦和不便。在这项研究中，我们开发了一种长效注射剂，利用相变机制进行辅助生殖技术（ART）的长期治疗。所选成分均具有良好的生物相容性。药代动力学研究表明，负载PRG的磷脂相变凝胶（PRG- pptg）连续释放PRG超过7 天。值得注意的是，药理学研究表明，每周服用prg - pptg可有效促进子宫发育。我们的研究结果表明，prg - pptg成功地实现了防止突发释放和减少给药频率，突出了pptg作为疏水药物长效复合体系的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Pharmaceutics and Biopharmaceutics 医学-药学

CiteScore

8.80

自引率

4.10%

发文量

211

审稿时长

36 days

期刊介绍： The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics. Topics covered include for example: Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids) Aspects of manufacturing process design Biomedical aspects of drug product design Strategies and formulations for controlled drug transport across biological barriers Physicochemical aspects of drug product development Novel excipients for drug product design Drug delivery and controlled release systems for systemic and local applications Nanomaterials for therapeutic and diagnostic purposes Advanced therapy medicinal products Medical devices supporting a distinct pharmacological effect.